Receptor-type protein tyrosine phosphatases in cancer

Texto completo

(1)$IJOFTF+PVSOBMPG$BODFS. 3FWJFX. 3FDFQUPS-UZQFQSPUFJOUZSPTJOFQIPTQIBUBTFTJODBODFS :V%V BOE+FOOJGFS3(SBOEJT . "CTUSBDU 1SPUFJO UZSPTJOF QIPTQIBUBTFT 151T QMBZ BO JNQPSUBOU SPMF JO SFHVMBUJOH DFMM TJHOBMJOH FWFOUT JO DPPSEJOBUJPO XJUI UZSPTJOF LJOBTFT UP DPOUSPM DFMM QSPMJGFSBUJPO BQPQUPTJT TVSWJWBM NJHSBUJPO BOE JOWBTJPO 3FDFQUPS-UZQF QSPUFJO UZSPTJOF QIPTQIBUBTFT 1513T BSF B TVCHSPVQ PG 151T UIBU TIBSF B USBOTNFNCSBOF EPNBJO XJUI SFTVMUJOH TJNJMBSJUJFT JO GVODUJPO BOE UBSHFU TQFDJGJDJUZ *O UIJT SFWJFX XF TVNNBSJ[F HFOFUJD BOE FQJHFOFUJD BMUFSBUJPOT JODMVEJOH NVUBUJPO EFMFUJPO BNQMJGJDBUJPO BOE QSPNPUFS NFUIZMBUJPOPG1513TJODBODFSBOEDPOTJEFSUIFDPOTFRVFODFTPG1513BMUFSBUJPOTJOEJGGFSFOUUZQFTPG DBODFST8FBMTPTVNNBSJ[FSFDFOUEFWFMPQNFOUTVTJOH1513TBTQSPHOPTUJDPSQSFEJDUJWFCJPNBSLFST BOEPSEJSFDUUBSHFUT*ODSFBTFEVOEFSTUBOEJOHPGUIFSPMFPG1513TJODBODFSNBZQSPWJEFPQQPSUVOJUJFTUP JNQSPWFUIFSBQFVUJDBQQSPBDIFT ,FZ XPSET 3FDFQUPS-UZQF QSPUFJO UZSPTJOF QIPTQIBUBTFT 1513T DBODFS NVUBUJPO EFMFUJPO BNQMJGJDBUJPO QSPNPUFSNFUIZMBUJPO. Signaling pathways are coordinately controlled by a balance between activators, such as protein tyrosine kinases (TKIs), and inactivators, including protein tyrosine phosphatases (PTPs). To date, cancer biology and drug development has primarily focused on TKIs, with relatively little understanding about the contribution of PTPs to regulate signal transduction in cancer cells[1-3]. In the human genome, the 107 PTPs can be divided into four families according to differences in the amino acid sequence of catalytic domains and in evolutionary development: class I cysteine-based PTPs, class II cysteine-based PTPs, class III cysteine-based PTPs, and Aspbased PTPs. The largest family of the four, the 99-member class I cysteine-based PTPs, can be further grouped into two subfamilies:

(2)

(3)

(4)

(5)

(6)

(7)

(8) PTPs (PTPRs) and 17 non-receptor PTPs (NRPTPs); and VH1-like

(9)

(10)

(11)

(12) substrates in addition to pTyr[4].

(13)

(14) !" PTPRB, PTPRC, PTPRD, PTPRE, PTPRF, PTPRG, PTPRH, PTPRJ, PTPRK, PTPRM, PTPRN, PTPRN1, PTPRO, PTPRQ, PTPRR, PTPRS, PTPRT, PTPRU, PTPRZ, and PTPRZ1), which are "VUIPST "GGJMJBUJPOT %FQBSUNFOU PG 0UPMBSZOHPMPHZ 6OJWFSTJUZ PG 1JUUTCVSHI4DIPPMPG.FEJDJOF 1JUUTCVSHI 1" 64"%FQBSUNFOU PG1IBSNBDPMPHZBOE$IFNJDBM#JPMPHZ 6OJWFSTJUZPG1JUUTCVSHI4DIPPM PG.FEJDJOF 1JUUTCVSHI 1" 64"4DIPPMPG.FEJDJOF 5TJOHIVB 6OJWFSTJUZ #FJKJOH 13$IJOB $PSSFTQPOEJOH"VUIPS+FOOJGFS3(SBOEJT -PUISPQ4USFFU &ZF BOE&BS*OTUJUVUF#VJMEJOH 4VJUF 6OJWFSTJUZPG1JUUTCVSHI4DIPPMPG .FEJDJOF 1JUUTCVSHI 1" 64"5FM

(15) ---'BY

(16) --&NBJMKHSBOEJT!QJUUFEV EPJDKD. XXXDKDTZTVDPN. largely homologous in structure and function. PTPRs consist of a transmembrane domain, unequal number of extracellular domains, and intracellular catalytic domains. Immunoglobulin-like domains and #

(17) $

(18) %

(19) &

(20)

(21) arranged in tandem. The catalytic activity mainly resides in the membrane-proximal domain (D1) for many PTPRs with the exception " # '* activities[5]&+ '# play an important role in maintaining the stability of the whole protein and regulating protein dimerization[6]. PTPRs are tightly regulated in cell signaling by a variety of mechanisms including post-translational modifications and/or dimerization[7-9]. Reversible oxidation is another important mechanism for regulating PTPR activity. The invariant cysteine residue in the active site of PTPRs has a low pK 2 , which makes it susceptible to oxidation[10]. In PTP1B, the sulfenic acid, which is displayed when the cysteine is oxidized, is converted to a cyclic sulfenamide structure to #

(22) !

(23)

(24)

(25) acid[11]. The inactive sulfenamide structure can be reverted to cysteine with reducing agents, thus providing a reversible mechanism of PTPR activation. Tyrosine phosphorylation has a crucial role in the regulation of physiological processes such as cell proliferation, differentiation, adhesion, and migration, which are closely relevant to human diseases, especially cancer. Genetic and epigenetic alterations such as copy number changes, mutation, and promoter methylation contribute to the expression level and/or function of PTPR proteins. Numerous PTPRs are reported to be involved in a variety of. $"$". $IJOFTF"OUJ-$BODFS"TTPDJBUJPO .

(26) :V%VFUBM. 3FDFQUPS-UZQF151TBOEDBODFSTJHOBMJOH. cancers8<. Although PTPRs share similar basic structures and the conserved cysteine in active sites, individual PTPRs have specific targets and thereby play different roles in cancer. This review focus on the impact of PTPR alterations across a spectrum of cancers and the clinical implications of targeting PTPRs therein.. (FOFUJDBOE&QJHFOFUJD"MUFSBUJPOTPG 1513T Genetic alterations that are frequently seen in cancers include

(27) # =

(28) #

(29) & Gain-of-function mutations can increase the activity of an oncogene, and loss-of-function mutations may silence a tumor suppressor gene. > ?

(30)

(31) @

(32) Genome Atlas (TCGA) data (summarized in Figure 1). Mutation appears to be the most common mechanism by which PTPRs are !

(33)

(34)

(35) #

(36) or loss.. PTPRT is the most frequently mutated PTPR in human cancers. Wang et al .[13] reported that PTPRT LX

(37)

(38)

(39)

(40) @@*LX!

(41)

(42)

(43) YX!

(44)

(45) & They tested the functional consequences of 5 mutations in the catalytic domains of PTPRT and all 5 showed reduced phosphatase activity compared with wild-type PTPRT , indicating that these are loss-of-function mutations[13]. PTPRT mutation has also been reported in other cancers including head and neck squamous cell carcinoma (HNSCC)[14], acute myeloid leukemia[15], and T-cell large granular lymphocytic[16]. Functional analysis of PTPRT mutation in HNSCC revealed that normal function, signal transducer and activator of transcription 3 (STAT3) dephosphorylation, was abrogated for the mutant protein[17]. PTPRD is the second most commonly mutated PTPR across all human cancers. PTPRD mutation has been reported in cutaneous squamous cell carcinoma 8Y<, glioblastoma multiforme (GBM) [19], melanoma[19], CRC8?<, HNSCC[14], and lung cancer8<. Functional studies of PTPRD mutation in neuroblastoma, melanoma, and GBM showed that mutation inactivated the function of PTPRD and. PTPR genetic alterations in cancers 9. Mutation Deletion. Y. "

(46) n.

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

(48) :V%VFUBM. that cancer cells harboring PTPRD mutations displayed decreased viability, thus suggesting PTPRD acts as a tumor suppressor in these cancers8^_`<. Wang et al .[13] j_X*PTPRF mutations @@^X*!

(49)

(50) ^X*#

(51)

(52) &+ mutation was also reported in HNSCC[14]. Behjati et al .8|< reported 14 PTPRB mutations in 10 of the 39 angiosarcomas studied. In tumors that were secondary and/or had MYC amplification, which is a radiation-associated biomarker of secondary angiosarcoma, the PTPRB `|X ?

(53) *& ~ # !!

(54) ! mutations of PTPRB are considered driver events in angiosarcoma. Copy number loss/deletion is common in cancers. Homozygous deletion usually contributes to loss of function of tumor suppressor genes. Many PTPRs negatively regulate cell proliferation, migration, and invasion, and homozygous deletion of these PTPRs may contribute to carcinogenesis. One of the most frequently deleted PTPRs is PTPRD . Homozygous or heterozygous loss of this gene has been reported in cutaneous squamous cell carcinoma8Yj<, GBM8^`<, lung cancer 8L<, metastatic melanoma 8Y^<, neuroblastoma [30], squamous cell carcinoma of the vulva[31], hepatocellular carcinoma8_<, and laryngeal squamous cell carcinoma[33]. In addition, PTPRF deletion was reported in pheochromocytomas [34]. Down-regulation of PTPRF , considered a tumor suppressor in many cancers, was reported in liver cancer, gastric cancer, and CRC[35]. Promoter methylation is an epigenetic mechanism of regulating gene expression. Tumor suppressors are often silenced by promoter hypermethylation in cancer. Promoter methylation is also an important mechanism for PTPR inactivation in cancer. PTPRG is hypermethylated in multiple cancers including breast cancer[36], gastric cancer[37], nasopharyngeal carcinoma8_Y<, Lynch syndrome CRC[39], childhood acute lymphoblastic leukemia[40], and cutaneous T-cell lymphoma [41]. PTPRG expression is negatively correlated with methylation, and when treated with methylation-suppressive ! $ | %

(55) PTPRG expression can be recovered[37,41]. A study of childhood acute lymphoblastic leukemia suggested that PTPRG methylation is induced by Ras mutations[40]. Promoter hypermethylation is also the primary mechanism of PTPRO dysregulation. PTPRO hypermethylation has been reported in hepatocellular carcinoma8``_<, colon cancer[44], lung cancer[45], and chronic lymphocytic leukemia[46]. You et al .[47] explored the potential of PTPRO as a biomarker in esophageal squamous cell carcinoma. They found PTPRO L|&?XL_j* _j&X__j*

(56) # no PTPRO methylation was observed in normal peripheral blood from 10 healthy subjects, suggesting PTPRO methylation is an epigenetic biomarker for noninvasive diagnosis of esophageal squamous cell carcinoma[47]. A study of breast cancer showed that PTPRO methylation was associated with lymph node involvement (P = 0.014), poorly differentiated histology (P = 0.037), depth of invasion (P = ?&??`*

(57) P = 0.001)8`Y<. PTPRO methylation

(58) |`X|_^Y*# _`X__^Y* of matched peripheral blood samples from patients with breast cancer but in none of the normal peripheral blood samples from 30 healthy. XXXDKDTZTVDPN. 3FDFQUPS-UZQF151TBOEDBODFSTJHOBMJOH. individuals8`Y<. Taken together, PTPRO methylation may represent a biomarker for noninvasive diagnosis and a prognostic factor in breast cancer. Other PTPRs reported to be hypermethylated in cancer include PTPRD , PTPRF, PTPRJ, PTPRM, PTPRR, PTPRT, and PTPRZ1 . In particular, PTPRD was found to be methylated in CRC, breast cancer, HNSCC, and GBM8`<. PTPRF hypermethylation is associated with phenobarbital-induced liver tumorigenesis[49], whereas PTPRJ

(59) #

(60)

(61) with early-onset CRC[50]. Moreover, Laczmanska et al .[51] reported hypermethylation of PTPRM , PTPRR , PTPRT , and PTPRZ1 in sporadic CRC compared to non-cancer people. Copy number amplification generally leads to gene overexpression and protein activation and is a common genetic alteration of oncogenes. Several PTPR genes, including PTPRC , PTPRR , and PTPRQ , are reportedly amplified in human cancers. PTPRC has the highest proportion of copy number amplifications among the PTPR genes, based on data for all cancers in the TCGA database. More specifically, PTPRC `&X |_?*

(62) j

(63)

(64)

(65) !&X?Y ^j*#

(66)

(67) _&jXL^^* cancer samples. PTPRQ and PTPRR

(68)

(69)

(70) Y&LX_|?*L&_Xj|?*

(71) samples in the TCGA repository. Furthermore, in samples in the TCGA repository, melanomas, lung adenocarcinomas, and sarcomas with PTPRR

(72) #

(73) ! PTPRR mRNA

(74) #

(75) +! ). PTPRA copy gains have also been reported for some cancers. Junnila et al . 8|< conducted an array-based analysis of gene expression and copy number levels using gastric cancer samples and then validated the results using the affinity capture-based transcript analysis (TRAC assay) and real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR). In their study, PTPRA copy number gain was detected in 5 of 13 primary gastric tumors and 3 of 7 gastric cell lines, and PTPRA overexpression was associated with copy number gain. Ardini et al . [53] reported PTPRA % ^X#

(76)

(77) high expression of PTPRA was associated with low tumor grade and positive estrogen receptor status. Furthermore, PTPRA overexpression in breast cancer cells inhibited cell growth, causing accumulation of cells in G0 or G1 phase[53]. Other PTPR genes that gain copies in cancer include PTPRF and PTPRH . PTPRF amplification was reported in a small cell lung cancer cell line and has also been observed in liver cancer8Y|`<. PTPRH is also overexpressed in CRC[55]. Seo et al .[55] found no PTPRH expression in normal colon tissue but detected % &YXL* `?X^ `Y*

(78)

(79) !! ! % PTPRH may occur late in CRC tumorigenesis. Overall, the functional consequences of PTPR !

(80) & In summary, PTPR dysregulation in cancer occurs through several mechanisms. These include mutation, which is the most common mechanism; deletion and promoter methylation, which. $IJO+$BODFS7PM*TTVF .

(81) :V%VFUBM. 3FDFQUPS-UZQF151TBOEDBODFSTJHOBMJOH. TCGA melanoma P ˘ 0.0009. TCGA lung adenocarcinoma 5,000. P = 0.0009. 600. 4,000 400. 3,000 ???. ??. 1,000 0. 0 \@\""

(82) . 3,000. \@\""

(83) . TCGA sarcoma P ?&?`Y. ???. 1,000. 0 \@\""

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cause PTPR inactivation; and gene amplification, though the functional consequences and role of this mechanism require further study.. 15133FHVMBUJPOPG$FMM4JHOBMJOHJO $BODFS PTPRs play important roles in controlling cell signaling. Thus, dysregulation of PTPRs leads to signaling alterations.. $FMMQSPMJGFSBUJPO BQPQUPTJT BOETVSWJWBM PTPRA was reported to dephosphorylate c-Src at inhibitory site |L #

(85) ! [56]. Ardini et al .[53] reported that PTPRA overexpression in breast cancer cells inhibited cell growth and caused cells to accumulate in G0 and G1 phase, suggesting PTPRA plays a tumor suppressor role in breast cancer. In estrogen-. $IJO+$BODFS7PM*TTVF. receptor–negative breast cancer cell lines as well as colon cancer cell lines, siRNA-mediated knockdown of PTPRA reduced Src activity and induced apoptosis[57]. Meyer et al .8|Y< found that inhibition of "

(86) ! #

(87)

(88)

(89) decreased Akt phosphorylation. PTPRA is also an important regulator of cell signaling. PTPRE protein dephosphorylates the C-terminal inhibitory sites of Src, Yes, and Fyn, leading to activation of Src family kinases[59]. Further analysis by Kraut-Cohen et al .[60] reveals that, in the absence of

(90) #

(91)

(92)

(93) inhibits the mitogen-activated protein kinase (MAPK) pathway.

(94) # ~ of Shc and blocks the interaction of PTPRE to Shc, leading to Src activation[60]. PTPRA was reported to regulate a candidate tumor suppressor,

(95)

(96) $ '"* `^=`^

(97) with Src by dephosphorylating or phosphorylating DARK[61]. In a study. $IJOFTF+PVSOBMPG$BODFS.

(98) :V%VFUBM. in hepatoma cells, Bera et al .[35] found that cell-cell contact during cell proliferation activated PTPRF, which in turn inhibited extracellular related kinase (ERK)-dependent signaling. In prostate cancer, overexpression of PTPRF decreased cell survival, inhibited insulinlike growth factor-1 receptor (IGF-1R) phosphorylation, and enhanced poly (ADP-ribose) polymerase (PARP) cleavage in the presence of neuroendocrine-derived medium8j<. A study of PTPRG PTPRG inhibited breast tumor formation in vivo and that PTPRG up ! cip Lkip ! = in a breast cancer cell model[36]. In nasopharyngeal carcinoma, overexpression of PTPRG suppressed tumor growth in vivo . PTPRG also induced G0/G1 phase arrest through down-regulation of cyclin D1 and stabilization of pRB8_Y<. Furthermore, PTPRG is considered a tumor suppressor in chronic myeloid leukemia. In addition to interacting with breakpoint cluster region/ABL proto-oncogene 1, nonreceptor tyrosine kinase (BCR/ABL) and v-crk avian sarcoma virus CT10 oncogene homolog-like (CRKL) through its intracellular domain, PTPRG, when overexpressed, inhibited BCR/ABL-dependent signaling, whereas down-regulation of PTPRG increased colony formation in chronic myeloid leukemia models[63]. PTPRH affects signaling events related to cell proliferation, apoptosis, and survival. Takada et al . [64] reported that PTPRH induced apoptotic cell death by at least two potential mechanisms, based on their results using a fibroblast cell line model: inhibiting Akt and integrin-linked kinases, which are both downstream of phosphoinositide 3-kinase (PI3K), and activating caspase activity. PTPRJ regulates Src activity. Namely, after phosphorylation at _ _?

(99) + |^ #

(100)

(101) it, and caused vascular endothelial growth factor (VEGF)-induced phosphorylation of vascular endothelial (VE)-cadherin and cortactin[65,66]. In contrast to PTPRJ, PTPRB suppresses angiogenesis by ! +

(102) # #! angio-genesis-related signaling8|jL<. STAT3 is an important regulator of cell proliferation and survival. Two PTPRs regulate STAT3 phosphorylation at Y705. When mutated, deleted, or hypermethylated in cancer, PTPRT and PTPRD drive hyperactivation of STAT3, which is accompanied by cell proliferation and, likely, migration in multiple cancers8LjY L<.. .JHSBUJPO JOWBTJPO BOENFUBTUBTJT PTPRA is reported to interact with focal adhesion kinase (FAK) at Y407 in breast cancer8L<. Suppression of PTPRA resulted in increases in FAK phosphorylation, formation of new focal adhesion kinase complexes, and increases in migration. Using colon cancer cells as a model, Krndija et al .[73] found that PTPRA expression is required for invasion into the chorioallantoic membrane. Overexpression of PTPRF #

(103) and reduced epithelial cell migration. Overexpression of PTPRF also inhibited tumor formation in nude mice[74]. PTPRF has been implicated to connect noninfiltrating GBM tumor cells to the extracellular. XXXDKDTZTVDPN. 3FDFQUPS-UZQF151TBOEDBODFSTJHOBMJOH. glycosylated chondroitin sulfate proteoglycans (CSPGs) which serve as the central organizer of GBM tumor microenvironment. Those !

(104) @ # !~

(105) [75]. PTPRH also plays an important role in migration. Expression of PTPRH induced dephosphorylation of p130cas, a focal adhesion

(106) +" jdok in the integrin signaling pathway. Overexpression of PTPRH disrupted the actin-based cytoskeleton and inhibited various integrin-promoted signaling processes[76]. Overexpression of PTPRJ decreased platelet-derived growth factor receptor (PDGFR) signaling by dephosphorylation and inhibition of the MAPK pathway. However, PTPRJ overexpression

(107) #

(108)

(109)

(110) in aberrant cell-substratum interactions[77]. In conclusion, PTPR alterations collectively play an important role in modulating cell signaling, leading to effects on proliferation, apoptosis, survival, migration, invasion, and metastasis.. $MJOJDBM*NQMJDBUJPOT Few drugs available to date directly target PTPRs. Several studies have investigated the clinical implication of PTPRs in the setting of cancer treatment. PTPRC is reportedly related to response to radiotherapy in the NCI-60 cancer cell collection8LY<. A recent report describes a 7-gene signature that predicts relapse and survival for early stage cervical carcinoma, namely PTPRF , ubiquitin-like 3 (UBL3 ), fibroblast growth factor 3 (FGF3 ), BMI1 proto-oncogene,

(111) #! ! BMI1 ), platelet-derived growth factor receptor, alpha polypeptide (PDGFRA ), replication factor C (activator 1) 4 (RFC4 ), and nucleolar protein 7 (NOL7 )[79]. Recurrence-free survival was worse for patients with the signature compared with those without[79]&\##

(112) +

(113)

(114) !! + %

(115)

(116) plasma or tissue-based biomarker in prostate cancer8Y?<. PTPRF inhibitors are currently in development. Yang et al .8Y< used a high-throughput screening assay to identify potential inhibitors + ' Y

(117)

(118)

(119) +

(120) #&"et al .8Y< used in silico assays, including pharmacophore mapping and 3D database searching, followed by SADMET-based virtual screening, docking %

(121)

(122) Y%

(123) + inhibitors. PTPRJ # ! many human cancers including breast cancer8Y_<, pancreatic cancer8Y`<, and colon cancer8Y|<. Paduano et al .8Yj< ! library a PTPRJ agonist peptide that binds and activates PTPRJ, leading to reduced MAPK phosphorylation, increased protein level

(124)

(125)

(126) # LKip1, reduced proliferation, and increased apoptosis. Ortuso et al .8YL< also discovered a PTPRJ agonist peptide, PTPRJ-pep19.4, and determined that the peptide inhibited in vitro # = # cancer cells but had no effect on primary normal human mammary endothelial cells. Although there is limited clinical data on drugs that directly target PTPRs, PTPRs have been investigated as biomarkers for treatment. $IJO+$BODFS7PM*TTVF .

(127) :V%VFUBM. or prognosis in different cancers. In addition, PTPR inhibitors and agonists are under development. Challenges in the development of PTPR-targeted therapies include the homology of PTPR catalytic domains8< and the susceptibility of the active site of most PTPRs to oxidation. Further research is needed on the effect of current and emerging drugs in vivo . In conclusion, PTPRs are a group of PTPs that share great structural similarity and play key roles in cell signaling. Alterations of. 3FDFQUPS-UZQF151TBOEDBODFSTJHOBMJOH. these phosphatases, whether by mutation, deletion, amplification, or promoter methylation, are reported to cause aberrations in crucial cellular pathways related to proliferation, apoptosis, survival, migration, and invasion, suggesting these PTPRs are critical components in carcinogenesis. Therefore, efforts to determine how best to target PTPRs are warranted.

(128) ?` ?Y Y

(129)

(130) ?` ?^ |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–. <> -VP- 4IFO(2 4UJGGMFS," FUBM-PTTPGIFUFSP[ZHPTJUZJOIVNBO. . BCFSSBOU DSZQU GPDJ "$' B QVUBUJWF QSFDVSTPS PG DPMPO DBODFS. XXXDKDTZTVDPN. $IJO+$BODFS7PM*TTVF .

(134)